Menovar announced that Ningbo Menohua Tiankang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for Tofacib citrate sustained-release tablets approved and issued by the State Drug Administration. The registration classification is 4 types of chemicals, with a specification of 11 mg. The indications are rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. The approval number is valid until October 12, 2031. The approval of the drug indicates that the company has obtained its domestic production and sales qualification, which can enrich the formulation product pipeline. As of the announcement date, the company has invested a total of 9.9685 million yuan in R&D expenses for this drug, and there is uncertainty about the future sales of this drug.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.